BeiGene
ONC
#734
Rank
ยฃ19.91 B
Marketcap
ยฃ171.34
Share price
-0.76%
Change (1 day)
61.94%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (ONC) - Total liabilities

Total liabilities on the balance sheet as of December 2024 : ยฃ1.93 Billion

According to BeiGene 's latest financial reports the company's total liabilities are ยฃ1.93 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BeiGene - Total liabilities on balance sheet (from 2014 to 2024)

Total liabilities by year

Year Total liabilities Change
2024-12-31ยฃ2.06 B15.88%
2023-12-31ยฃ1.78 B7.9%
2022-12-31ยฃ1.64 B-7.32%
2021-12-31ยฃ1.78 B40.14%
2020-12-31ยฃ1.27 B162.77%
2019-12-31ยฃ0.48 B23.71%
2018-12-31ยฃ0.39 B45.79%
2017-12-31ยฃ0.26 B525.12%
2016-12-31ยฃ42.87 M49.7%
2015-12-31ยฃ28.64 M60.1%
2014-12-31ยฃ17.88 M-41.59%
2013-12-31ยฃ30.62 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
ยฃ9.08 M-99.53%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ0.62 B-67.75%๐Ÿ‡บ๐Ÿ‡ธ USA